ATR inhibitors |
Berzosertib (M6620; VX-970) | Ib/II | Recurrent platinum-sensitive ovarian cancer that is resistant to PARPi Part A: Safety run-in of carboplatin (AUC 5 D1) + avelumab (1600 mg D1) + berzosertib (90 mg/m2 D2), every 3 weeks. Dose de-escalations of berzosertib are allowed to 60 mg/m2 or 40 mg/m2 Part B: Patients are randomized to standard of care chemotherapy ± bevacizumab (carboplatin + paclitaxel/gemcitabine/pegylated liposomal doxorubicin ± bevacizumab) followed by maintenance bevacizumab, or the combination of carboplatin + avelumab + berzosertib for six cycles followed by avelumab maintenance until disease progression or intolerable toxicity
| | NCT03704467 |
BAY1895344 | Ib | Advanced solid tumors with dose expansion cohort in patients with DDR-deficiency biomarker positive gynecological cancers, gastric, breast, and prostate cancer Patients are treated with BAY1895344 + pembrolizumab
| | NCT04095273 |
CHK1/2 inhibitors |
Prexasertib | I | | | NCT03495323 |
CDK inhibitors |
Ribociclib | I | | | NCT03294694 |
DNA-PKcs inhibitors |
Nedisertib; M3814 | I | Advanced solid tumors, and who are amenable to radiotherapy Patients are treated with nedisertib + avelumab ± palliative radiotherapy
| | NCT03724890 |